Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis.

[1]  H. Huland,et al.  Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. , 1990, The Journal of urology.

[2]  H. Huland,et al.  Urindiagnostik oberflächlicher Harnblasentumoren durch Zytologie, Immunzytologie und Flowzytometrie , 1988 .

[3]  V. Laudone,et al.  An overview of intravesical therapy for superficial bladder tumors. , 1987, The Journal of urology.

[4]  H. Huland,et al.  Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology. , 1987, The Journal of urology.

[5]  H. Huland,et al.  Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. , 1987, The Journal of urology.

[6]  H. Huland,et al.  Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. , 1984, The Journal of urology.

[7]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[8]  J. Rowe,et al.  The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. , 1978, The Journal of urology.

[9]  R. Barnes,et al.  Changes in grade and stage of recurrent bladder tumors. , 1977, The Journal of urology.

[10]  A. Althausen,et al.  Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. , 1976, The Journal of urology.

[11]  R. Schade,et al.  The association of urothelial atypism with neoplasia: its importance in treatment and prognosis. , 1973, The Journal of urology.